ST elevation myocardial infarction anticoagulant and antithrombotic therapy: Difference between revisions
Jump to navigation
Jump to search
New page: {{SI}} {{CMG}} {{EJ}} ==Overview== ==References== {{SIB}} {{WH}} {{WS}} |
|||
| Line 7: | Line 7: | ||
==Overview== | ==Overview== | ||
==Sites of Action of Antithrombins== | |||
===Parenteral Drugs Targeting Factor Xa=== | |||
[[Fondaparinux]] | |||
Idraparinux | |||
===Oral Drugs Targeting Factor Xa=== | |||
[[Rivaroxaban]] | |||
Apixaban | |||
LY517717 | |||
YM150 | |||
DU-176b | |||
PRT-054021 | |||
==References== | ==References== | ||
Revision as of 23:47, 21 April 2009
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Sites of Action of Antithrombins
Parenteral Drugs Targeting Factor Xa
Fondaparinux Idraparinux
Oral Drugs Targeting Factor Xa
Rivaroxaban Apixaban LY517717 YM150 DU-176b PRT-054021